FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy
Related Topics >> Drug Discovery | Deals | Genzyme

Myozyme approval leads to rich royalty pact

Genzyme's success in gaining approval for Myozyme, an enzyme replacement therapy for the extremely rare Pompe disease, is proving a boon for the biotech that originally developed it. Synpac, a subsidiary of a Taiwanese company, agreed to a 15-year royalty sharing deal for Myozyme that will net up to $821 million. Genzyme licensed the therapeutic in 2000 for Pompe's disease.

- here's the report on the pact from BiotechEast

More stories about Genzyme  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 3 + 20?
To combat spam, please solve the math question above.